NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
klk1medical
KLK1 is a human gene that makes a small enzyme involved in controlling fluids and inflammation in tissues — think of it like a local thermostat that helps regulate pressure and repair where the body is injured. Investors watch KLK1 when it appears in drug development or diagnostic work because changes in its activity can be a target for medicines or a marker used to decide if a treatment is working, and clinical or regulatory news about such uses can materially affect a company's prospects.
recombinanttechnical
Recombinant describes a product made by combining genetic material from different sources so cells can be used as tiny factories to produce a desired protein, vaccine ingredient or enzyme. For investors, the label signals a biotechnology approach that can enable scalable manufacturing, patent protection and targeted therapies, but also brings specific regulatory review, production complexity and clinical risk — similar to a customized recipe that can yield high value but needs precise execution.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
MINNEAPOLIS--(BUSINESS WIRE)--
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on July 15, 2026, it granted options to purchase an aggregate of 160,000 shares of DiaMedica’s common stock to a newly hired non-executive employee whose employment commenced in July 2026. The stock options were a material inducement to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of their compensation.
The stock options were approved by the Compensation Committee of the Board of Directors and issued under the DiaMedica Therapeutics Inc. Amended and Restated 2021 Employment Inducement Incentive Plan. The options have an exercise price of $7.64 per share, which is equal to the closing price of the Company’s common stock on July 15, 2026, and are scheduled to vest and become exercisable, on a cumulative basis, with respect to 25% of such underlying shares on the one-year anniversary of the grant date and with respect to the remaining 75% of such underlying shares in 12 quarterly installments commencing three months after the one-year anniversary of the grant date, subject to the employee’s continued service with the Company. The options have a ten-year term.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction, and acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information, visit the Company’s website at www.diamedica.com.
